StockNews.AI
ARTV
StockNews.AI
13 days

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

1. First patient treated in global trial for AlloNK® and autoimmune diseases. 2. Over a dozen patients treated across various autoimmune trials. 3. Initial safety and data for AlloNK to be shared by year-end 2025. 4. Artiva has a cash runway until Q2 2027 with $142.4 million available. 5. Initial clinical response data for AlloNK expected in first half of 2026.

Earnings
-8.01%Current Return
VS
-0.07%S&P 500
$2.8708/06 04:19 PM EDTEvent Start
$2.6408/07 11:14 PM EDTLatest Updated
12m saved
Insight
Article

FAQ

Why Bullish?

The progress in clinical trials and strong cash reserves indicate positive future developments. Historical examples show clinical advancements often correlate with rising stock prices.

How important is it?

The advancements in AlloNK's clinical trials are significant for ARTV’s valuation and future growth prospects.

Why Long Term?

The anticipated release of trial data in late 2025 and 2026 can drive sustained interest and investment in ARTV.

Related Companies

MRNACRSPEDIT
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases Initial safety, translational data, and lead indication selection for AlloNK in autoimmune diseases to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Cash runway into Q2 2027, with cash, cash equivalents, and investments of $142.4 million as of June 30, 2025 SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2025, and highlighted recent progress. “We are making meaningful progress across our ongoing clinical trials exploring AlloNK® in autoimmune disease. We now have over a dozen sites enrolling across our trials in the US and have already treated over a dozen patients with AlloNK in combination with monoclonal antibodies across rheumatoid arthritis, SLE, lupus nephritis, Sjögren’s disease, and systemic sclerosis,” said Fred Aslan, M.D., Chief Executive Officer of Artiva. “By the end of 2025, we look forward to sharing initial translational data, supporting AlloNK’s mechanism of action, and safety data, supporting the potential of our therapy, which includes the use of cyclophosphamide and fludarabine, to be administered and managed in an outpatient setting across multiple autoimmune indications. We also look forward to announcing our lead indication by the end of 2025, setting the stage to share initial clinical response data in that indication in the first half of next year.” Recent Business Highlights AlloNK® (also known as AB-101) Updates Over a dozen clinical sites active and enrolling across two company-sponsored trials in autoimmune diseases: the Phase 2a basket clinical trial and the Phase 1/1b clinical trial in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN)First patient treated with AlloNK + rituximab in recently initiated global Phase 2a company-sponsored basket clinical trial for refractory rheumatoid arthritis (RA), Sjögren’s disease (SjD), idiopathic inflammatory myopathies (myositis, or IIM), and systemic sclerosis (scleroderma, or SSc)Over a dozen patients treated with AlloNK + monoclonal antibody (mAb) across refractory RA, SLE, LN, SjD, and SSc in the company-sponsored trials and an investigator-initiated basket trial Upcoming Milestones By Year-End 2025: Initial safety and translational data for AlloNK + mAb across multiple autoimmune diseases from ongoing clinical trials and disclosure of lead indication for further development Mechanistic and translational data for AlloNK in autoimmune diseasesInsights into tolerability of AlloNK + mAb, and the patient journey in community rheumatology sites, including the potential ease of use of conditioning regimens with cyclophosphamide and fludarabineDisclosure of lead indication for AlloNK development in autoimmune diseases 1H 2026: Initial clinical response data in the lead autoimmune indication from ongoing clinical trials with longer follow-up to inform registrational strategy Second Quarter 2025 Financial Results Cash, Cash Equivalents and Investments. As of June 30, 2025, Artiva had cash, cash equivalents, and investments of $142.4 million, which is expected to fund operations into Q2 2027Research and Development Expenses. Research and development expenses were $17.9 million for the three months ended June 30, 2025, compared to $12.3 million for the three months ended June 30, 2024General and Administrative Expenses. General and administrative expenses were $4.9 million for the three months ended June 30, 2025, compared to $3.9 million for the three months ended June 30, 2024Other Income (expense), net. Other income, net, was $1.6 million for the three months ended June 30, 2025, compared to other expense, net, of $1.7 million for the three months ended June 30, 2024Net Loss. Net loss totaled $21.3 million for the three months ended June 30, 2025, as compared to net loss of $17.8 million for the three months ended June 30, 2024, with non-cash stock-based compensation expense of $1.5 million for the three months ended June 30, 2025, and June 30, 2024 About Artiva Biotherapeutics Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases. This includes two company-sponsored trials, one in systemic lupus erythematosus for patients with or without lupus nephritis, and a basket trial across autoimmune diseases including rheumatoid arthritis and Sjögren’s disease, as well as an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs. Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the “Company”) regarding the potential benefits, accessibility, ease of use, effectiveness, safety and mechanism of action of AlloNK; the Company’s ability to advance AlloNK in autoimmune disease; the Company’s ability to demonstrate progress and clinical validation of its approach; the Company’s expectations regarding timing and availability of data from the Company’s clinical trials or the basket IIT; the timing related to the selection of a lead autoimmune indication; the timing, likelihood or success of the Company's business strategy, as well as plans and objectives of management for future operations; and the Company’s future results of operations and financial position, including cash runway. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.  Artiva Biotherapeutics, Inc.Condensed Balance Sheets(Unaudited)(in thousands)   June 30, 2025 December 31, 2024Assets    Cash, cash equivalents and investments $142,365  $185,428 Property and equipment, net  6,886   6,370 Operating and financing lease right-of-use assets  12,940   14,055 Other assets  7,200   3,728 Total assets $169,391  $209,581 Liabilities and stockholders' equity    Accounts payable and accrued expenses $7,053  $8,513 Operating and financing lease liabilities  13,224   14,354 Other liabilities  73   73 Total liabilities  20,350   22,940 Stockholders' equity  149,041   186,641 Total liabilities and stockholders' equity $169,391  $209,581        Artiva Biotherapeutics, Inc.Condensed Statements of Operations and Comprehensive Loss(Unaudited)(in thousands, except share and per share data)   Three Months Ended June 30, Six Months Ended June 30,   2025   2024   2025   2024 License and development support revenue $-  $-  $-  $251 Operating expenses:        Research and development  17,861   12,333   34,914   23,488 General and administrative  4,949   3,857   10,068   7,444 Total operating expenses  22,810   16,190   44,982   30,932 Loss from operations  (22,810)  (16,190)  (44,982)  (30,681)Other income (expense), net        Interest income  1,561   676   3,425   1,326 Change in fair value of SAFEs  —   (2,352)  —   (2,620)Other (expense) income, net  (5)  23   (8)  169 Total other income (expense), net  1,556   (1,653)  3,417   (1,125)Net loss $(21,254) $(17,843) $(41,565) $(31,806)Net loss per share, basic and diluted $(0.87) $(22.00) $(1.71) $(39.24)Weighted-average common shares outstanding, basic and diluted  24,378,823   811,210   24,360,502   810,484 Comprehensive loss:        Net loss $(21,254) $(17,843) $(41,565) $(31,806)Other comprehensive income (loss), net  2   (86)  131   (187)Comprehensive loss $(21,252) $(17,929) $(41,434) $(31,993)          ContactsInvestors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.comMedia: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com Source: Artiva Biotherapeutics, Inc.

Related News